Evidence map›Paper›PMID 37584393›Full record

ArticleMolecular oncology2023

Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.

Yu Wei, Tingwei Zhang, Beihe Wang, Jian Pan, Shengming Jin, Bangwei Fang, Weijie Gu, Xiaojian Qin, Bo Dai, Guowen Lin and 4 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yu WeiDepartment of Urology, Fudan University Shanghai Cancer Center, China.
Tingwei ZhangDepartment of Urology, Fudan University Shanghai Cancer Center, China.
Beihe WangDepartment of Urology, Fudan University Shanghai Cancer Center, China.
Jian PanDepartment of Urology, Fudan University Shanghai Cancer Center, China.ORCID 0000-0002-8361-7529
Shengming JinDepartment of Urology, Fudan University Shanghai Cancer Center, China.ORCID 0000-0001-8666-4606
Bangwei FangDepartment of Urology, Fudan University Shanghai Cancer Center, China.ORCID 0000-0002-3279-2140
Weijie GuDepartment of Urology, Fudan University Shanghai Cancer Center, China.
Xiaojian QinDepartment of Urology, Fudan University Shanghai Cancer Center, China.
Bo DaiDepartment of Urology, Fudan University Shanghai Cancer Center, China.
Guowen LinDepartment of Urology, Fudan University Shanghai Cancer Center, China.
Hualei GanDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Junlong WuDepartment of Urology, Fudan University Shanghai Cancer Center, China.ORCID 0000-0002-4125-7975
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, China.ORCID 0000-0003-4974-3780
Yao ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, China.ORCID 0000-0001-7950-6669
Shanghai Medical College of Fudan University · CN

Funding

Chinese Anti-Cancer Association Foundation CETSDHRCORP252-3-018Natural Science Foundation of Shanghai 23ZR1412200Program of Shanghai Academic Research Leader 23XD1420600Shanghai Medical Innovation Research Special Project 21Y11904300the General Program of Beijing Xisike Clinical Oncology Research Foundation Y-2019AZMS-0012the National Nature Science Foundation of China 82172621
6 · The paper itself

Abstract

Although there is a well-known disparity in prostate cancer (PC) incidence and mortality between Chinese and Western patients, the underlying genomic differences have been investigated only sparsely. This clinicogenomic study was conducted to reveal the genomic mutations contributing to the PC disparity across ethnicities and investigate the mutational profile of Chinese PC patients. A total of 1016 Chinese PC patients were prospectively enrolled and subjected to targeted sequencing, resulting in usable sequencing data for 41 genes from 859 patients. Genomic data retrieved from The Cancer Genome Atlas (TCGA; locoregional PC), Memorial Sloan Kettering Cancer Center [MSKCC; metastatic castration-sensitive PC (mCSPC)], and Stand Up To Cancer [SU2C; metastatic castration-resistant PC (mCRPC)] cohorts were used as comparators representing Western men. Genomic mutations were analyzed using an integrated bioinformatic strategy. A comparison of the disease stages revealed that mutations in tumor protein 53 (TP53), androgen receptor (AR), forkhead box A1 (FOXA1), and genes involved in the cell cycle pathway were enriched in mCRPC. Mutations in adenomatous polyposis coli (APC) gene were found to be more prevalent in patients with visceral metastasis. Genomic differences between Western and Chinese men were mainly observed in castration-sensitive PC, with tumors from Chinese men having more FOXA1 (11.4% vs. 4.2%) but fewer TP53 (4.8% vs. 13%) mutations in locoregional PC and harboring fewer TP53 (11% vs. 29.2%), phosphatase and tensin homolog (PTEN; 2.5% vs. 10.3%), and APC (1.7% vs. 7.4%) mutations in the mCSPC stage than those of Western men. Patients of both ethnicities with mCRPC had similar mutational spectra. Furthermore, FOXA1 class-2 was less common than FOXA1 class-1 and showed no enrichment in metastasis, contrary to the findings in the Western cohort. Our study provides a valuable resource for a better understanding of PC in China and reveals the genomic alterations associated with PC disparity across races.

Indexed as

East Asian PeopleGenomicsProstatic NeoplasmsAdenomatous Polyposis Coli ProteinAgedAged, 80 and overChinaHepatocyte Nuclear Factor 3-alphaHumansMaleMiddle AgedMutationProspective StudiesReceptors, AndrogenTumor Suppressor Protein p53Adenomatous Polyposis Coli ProteinAPC protein, humanFOXA1 protein, humanHepatocyte Nuclear Factor 3-alphaReceptors, AndrogenTP53 protein, humanTumor Suppressor Protein p53Chinese populationclinical sequencing cohortethnic disparityFOXA1prostate cancer

Identifiers

PMID37584393
PMCPMC10552897
OpenAlexW4385850383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.